PSMA-PET agents added to prostate imaging guidelines


The National Comprehensive Cancer Network added Telix Pharmaceuticals' 68Ga-PSMA-11 and Lantheus Medical Imaging's piflufolastat F-18 to its prostate cancer imaging guidelines. The updated guidance also said conventional imaging no longer is a prerequisite to PSMA-PET, PSMA-PET/CT or PSMA-PET/MRI can be an effective first line strategy, and Ga-68 PSMA-11 PET/CT or F-18 piflufolastat PSMA PET/CT can be alternatives to standard bone and soft tissue imaging.

Full story:

SNMMI SmartBrief

Nuclear medicine, molecular imaging and therapy

Designed specifically for nuclear medicine and molecular imaging professionals, SNMMI SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information to save you time and keep you informed on our profession.